RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean

Rapport Therapeutics, Inc.

Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.
Consolidated Phase 1 safety data (n=64) shows all TEAEs Grade 1/2, no SAEs; common: headache, dry mouth, brain fog, fatigue.
Upcoming catalysts: initiate Phase 2a in bipolar mania Q3 2025, update on diabetic neuropathic pain program 2H 2025.
Cash, cash equivalents and short-term investments of $285.4M as of March 31, 2025; runway through end of 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.